Sayfullin Artur Sidorovich (
Head of Oncology Department
antitumor drug therapy No. 2, BU Khanty-Mansi Autonomous Okrug-Yugra “Surgut District Clinical Hospital” (Surgut)
)
Morozova Yulia Andreevna (
Oncologist, BU Khanty-Mansi Autonomous Okrug-Yugra “Surgut District Clinical Hospital” (Surgut) )
Musaeva Saida Dinislamovna (Oncologist, BU Khanty-Mansi Autonomous Okrug-Yugra “Surgut District Clinical Hospital” (Surgut) )
Aksarin Alexey Alexandrovich (Doctor of Medical Sciences, BU Khanty-Mansi Autonomous Okrug-Yugra “Surgut District Clinical Hospital” (Surgut) )
Vidyushchenko Yulia Nikolaevna (Head of Oncology Department
antitumor drug therapy No. 1, BU Khanty-Mansi Autonomous Okrug-Yugra “Surgut District Clinical Hospital” (Surgut)
)
| |
Metastatic brain damage is associated with an unfavorable course of the disease and significantly affects the quality and life expectancy of patients with breast cancer (BC), and difficulties in therapy are due to the low ability of most drugs to overcome the blood-brain barrier. Hormone-positive HER2-negative breast cancer in some cases has a torpid course compared to other subtypes and is more common in the population. The breakthrough achieved in recent years in the treatment of hormone-positive HER2neu-negative metastatic breast cancer (mBC) is directly related to the emergence and widespread use of CDK4/6 inhibitors in clinical practice, which significantly improved not only progression-free survival, but also overall survival, incl. and in patients with brain metastases.
Keywords:clinical observations, HR+ HER2– mBC, CDK4/6 inhibitor, ribociclib, brain metastases, extended targeted therapy
|
|
| |
|
Read the full article …
|
Citation link:
Sayfullin A. S., Morozova Y. A., Musaeva S. D., Aksarin A. A., Vidyushchenko Y. N. CLINICAL CASES OF RIBOCICLIB IN THE TREATMENT OF HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: EXAMPLES OF USE IN BRAIN METASTASES AND AS LONG-TERM TARGETED THERAPY // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2024. -№01/2. -С. 92-100 DOI 10.37882/2223-2966.2024.1-2.13 |
|
|
